Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-101

Chemo like we saw with AIPAC is very effective at killing tumor cells and efti simply increased immunity with the antigens found it tumor debris. The trial failed, although that probably has more to do with its design created several years ago. It was a novel bold attempt. I believe the class of drugs known as APC activators will soon be a common addition, and efti as a subcutaneous shot is well positioned. So beyond chemo, I’m saying targeted therapies need to be tried. Current PD-1 combos need to be tried, as in efti would be the 3rd therapy. Instead of throwing massive resources at AIPAC PH3, let’s see 10 TACT-002 type trials across several targeted therapies. EOC is running a trial in MBC, imagine the value if efti shows benefits universally with many therapies? Just thinking out loud.